De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
ADMA Biologics Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
ADMA Biologics heeft een totaal eigen vermogen van $188.3M en een totale schuld van $131.1M, wat de schuld-eigenvermogensverhouding op 69.6% brengt. De totale activa en totale passiva bedragen respectievelijk $376.4M en $188.1M. De EBIT ADMA Biologics is $86.7M waardoor de rentedekking 4.7 is. Het heeft contanten en kortetermijnbeleggingen van $88.2M.
Belangrijke informatie
69.6%
Verhouding schuld/eigen vermogen
US$131.07m
Schuld
| Rente dekkingsratio | 4.7x |
| Contant | US$88.24m |
| Aandelen | US$188.27m |
| Totaal verplichtingen | US$188.13m |
| Totaal activa | US$376.40m |
Recente financiële gezondheidsupdates
Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Jul 17
Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Dec 02Recent updates
ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues
Oct 09ADMA Biologics: Riding High On ASCENIV's Success
Oct 02ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price
Sep 06ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality
Aug 16ADMA Biologics: A Compelling GARP Stock For Biotech Investors
Jul 27ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 24Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Jul 17Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?
May 30ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next
May 13Giving ADMA Biologics A Well-Deserved 'Booyah'
May 12ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares
May 08Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Apr 03ADMA Biologics: On A Roll Entering 2024
Jan 19Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?
Jan 09ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Jan 09We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet
May 12ADMA Biologics: Strong Growth Is Clearing The Path To Profitability
Aug 21ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M
Aug 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01ADMA Biologics: A Path To Profits Looks Clear
May 12ADMA: Pertinent Updates
Apr 18ADMA Biologics' 2021 Numbers Showed Continued Strong Execution
Mar 29ADMA Biologics: 2021 Was Tough
Jan 18ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Dec 02Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $303.7M ) ADMA } overtreffen de korte termijn passiva ( $44.2M ).
Langlopende schulden: De kortetermijnactiva ADMA ( $303.7M ) overtreffen de langetermijnschulden ( $144.0M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 22.7% ) ADMA wordt als voldoende beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van ADMA is de afgelopen 5 jaar gedaald van 175.6% naar 69.6%.
Schuldendekking: De schuld van ADMA wordt goed gedekt door de operationele kasstroom ( 55.7% ).
Rentedekking: De rentebetalingen op de schuld van ADMA worden goed gedekt door EBIT ( 4.7 x dekking).